Sermorelin for Adult Growth Hormone Deficiency: Off-Label Dosing Protocol

What Is Sermorelin and Why Is It Used Off-Label for Adult GHD?

Sermorelin acetate is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of human GHRH(1-44). It binds the GHRH receptor on anterior pituitary somatotrophs, triggering endogenous growth hormone (GH) release. The FDA approved sermorelin (as Geref Diagnostic) solely as a diagnostic agent for GHD in pediatric patients, not as a therapeutic agent for adults [1].

After Serono Laboratories withdrew Geref from the U.S. market in 2008, compounding pharmacies became the primary source for sermorelin acetate. Prescribers who use it in adults with documented GHD do so entirely off-label, meaning outside the boundaries of any FDA-approved indication. The Endocrine Society's 2011 clinical practice guideline on adult GHD management recommends recombinant human GH (somatropin) as the standard of care and does not include sermorelin among recommended therapies [2].

That distinction matters. Somatropin has decades of phase III trial data in adult GHD populations, including the key trials that led to FDA approval of products like Genotropin, Norditropin, and Humatrope. Sermorelin lacks equivalent data in adults. Clinicians who prescribe it typically cite its theoretical advantages: preservation of pulsatile GH secretion, activation of endogenous negative feedback loops, and a lower risk of supraphysiologic GH exposure compared to exogenous injection [3].

The practical reality is that sermorelin can only work if the patient retains functional somatotroph cells. In patients with organic GHD caused by pituitary surgery, radiation, or large adenomas, the pituitary may be unable to respond to GHRH stimulation. This is a fundamental limitation that shapes patient selection.

FDA-Approved Indications vs. Off-Label Use

The only FDA-approved indication for sermorelin was diagnostic evaluation of GHD in children with short stature. It was never approved for GHD treatment in any age group. That approval has been inactive since 2008 when Serono discontinued the product [1].

Off-label prescribing is legal in the United States. Physicians may prescribe any FDA-approved drug for a non-approved indication based on clinical judgment. However, sermorelin's situation is unusual because the branded product no longer exists. Current supply comes exclusively from 503A and 503B compounding pharmacies, which operate under different regulatory oversight than conventional pharmaceutical manufacturers [4].

The FDA has periodically scrutinized compounded peptides, including sermorelin. In 2019, the agency nominated several peptides (though not sermorelin specifically) for its "Bulks" list review under the Drug Quality and Security Act. Clinicians should verify that their compounding pharmacy holds appropriate state licensure and, for 503B outsourcing facilities, FDA registration [4].

Patients considering sermorelin should understand three points. First, insurance almost never covers compounded sermorelin for adult GHD. Second, potency and sterility depend entirely on the compounding pharmacy's quality controls. Third, no phase III randomized controlled trial has evaluated sermorelin specifically for treating adult GHD.

Clinical Evidence: What Do the Studies Actually Show?

The evidence base for sermorelin in adult GHD is thin. Most published data come from small, short-duration, open-label studies or extrapolations from pediatric growth data.

A 1997 study by Vittone et al. examined twice-daily subcutaneous GHRH(1-29) (sermorelin) at doses of 10 or 20 mcg/kg/day in healthy older men (ages 64 to 76, N=29) over 14 days. The higher dose increased 24-hour integrated GH secretion by roughly 70% compared to placebo [5]. This study was not conducted in patients with diagnosed adult GHD, and 14 days is far too short to evaluate meaningful body composition or quality-of-life outcomes.

Khorram et al. published a 2001 study (N=16 healthy elderly subjects, 9 men and 7 women, ages 60 to 85) using GHRH analog injections nightly for 16 weeks. IGF-1 levels increased significantly from baseline, and lean body mass showed modest gains measured by DEXA [6]. Again, this population did not meet formal diagnostic criteria for adult GHD per the Endocrine Society's definition (peak GH <5 mcg/L on provocative testing with appropriate clinical context) [2].

By contrast, somatropin's evidence in adult GHD includes multiple large, multicenter RCTs. The key trial supporting Genotropin's adult GHD indication enrolled 166 patients and demonstrated statistically significant improvements in lean body mass, fat mass, and lipid profiles over 6 months [7]. A 2009 Cochrane systematic review of recombinant GH in adult GHD analyzed 11 RCTs (N=534) and found small but consistent improvements in body composition, though quality-of-life effects were uncertain [8].

Dr. Kevin Yuen, an endocrinologist at the Barrow Neurological Institute and contributor to the Endocrine Society's GHD guidelines, has stated: "GHRH analogs like sermorelin presuppose intact pituitary function, which is exactly what many adult GHD patients lack. The standard of care remains recombinant GH, where we have strong efficacy and long-term safety data" [2].

The American Association of Clinical Endocrinologists (AACE) 2019 growth hormone update similarly positions somatropin as the standard therapy and does not recommend GHRH analogs for adult GHD treatment [9].

Dosing Protocol When Used Off-Label

For clinicians who elect to prescribe sermorelin off-label (after confirming the patient has residual pituitary somatotroph function), published dosing patterns and clinical experience converge on the following protocol. This is not an endorsed guideline but reflects the most commonly reported approach.

Starting dose: 200 to 300 mcg subcutaneously once daily at bedtime. Bedtime administration aligns with the physiological nocturnal GH surge. Some clinicians begin at 100 mcg in older patients or those with comorbidities and titrate upward over 2 to 4 weeks.

Injection technique: Subcutaneous injection into the abdomen (periumbilical region) or anterior thigh. Rotate sites to minimize lipodystrophy. Reconstituted sermorelin is stored at 2 to 8°C and typically expires 30 days after reconstitution, though this varies by compounding pharmacy.

Titration: Dose adjustments are guided by IGF-1 levels, targeting the age-adjusted mid-to-upper normal range. If IGF-1 remains below the lower third of normal after 6 to 8 weeks at 300 mcg nightly, the prescriber may consider the patient a non-responder (likely due to insufficient somatotroph reserve) and transition to somatropin.

Duration: Most clinicians prescribe an initial 3-to-6-month trial. Clinical endpoints include changes in IGF-1, body composition (assessed by DEXA), energy levels, and sleep quality. If no measurable improvement occurs by 6 months, continuation is difficult to justify.

Cycling: Some practitioners advocate 5-days-on/2-days-off protocols or periodic 4-week breaks to prevent tachyphylaxis (receptor desensitization). No controlled trial has validated any specific cycling protocol for sermorelin, and the physiological rationale remains theoretical.

Monitoring and Safety Considerations

Baseline labs before initiating sermorelin should include IGF-1, a comprehensive metabolic panel, fasting glucose or HbA1c, lipid panel, and thyroid function tests. GH stimulates hepatic glucose output and may worsen insulin resistance, so glycemic monitoring is particularly important in patients with pre-diabetes or type 2 diabetes [2].

The following schedule reflects standard monitoring practice:

Week 6: Repeat IGF-1. If the value has not risen meaningfully, confirm adherence and injection technique before increasing the dose.

Week 12: Repeat IGF-1, fasting glucose, and assess symptom response. This is the decision point for continuation.

Every 3 to 6 months thereafter: IGF-1, metabolic panel, and clinical assessment. IGF-1 should not exceed the age-adjusted upper limit of normal, as supraphysiologic IGF-1 is associated with increased risk of proliferative conditions [10].

Common side effects of sermorelin include injection site reactions (redness, swelling), transient flushing, headache, and dizziness. These tend to be mild and self-limited. Serious adverse effects are rare in published reports, though the limited sample sizes in existing studies preclude confident safety conclusions [5][6].

A specific safety concern with compounded peptides is product quality. A 2017 analysis published in JAMA Internal Medicine found that 22% of compounded sterile preparations tested had quality problems including subpotency, superpotency, or contamination [11]. Prescribers should request certificates of analysis (COAs) from their compounding pharmacy and verify third-party testing.

Who Is a Candidate (and Who Is Not)

Not every adult with GHD is a candidate for sermorelin. The key biological prerequisite is residual pituitary somatotroph function. Without functional GHRH receptors and viable GH-secreting cells, sermorelin cannot produce a meaningful response.

Potentially appropriate candidates: Adults with idiopathic or age-related GH decline (sometimes termed "adult-onset GHD" with partial somatotroph reserve) who have a documented subnormal GH response on provocative testing but whose pituitary is structurally intact on MRI. These patients may retain enough somatotroph mass to respond to GHRH stimulation.

Poor candidates: Patients with organic GHD from pituitary surgery, cranial radiation, large sellar/suprasellar tumors, or panhypopituitarism. In these cases, the somatotrophs are destroyed or severely damaged, and exogenous GHRH stimulation will fail. These patients should receive somatropin per Endocrine Society and AACE guidelines [2][9].

The GHRH stimulation test itself can serve as a predictor. If a patient shows a peak GH response of <5 mcg/L after a single diagnostic dose of GHRH (with or without arginine), they are unlikely to respond to chronic sermorelin therapy [12].

Dr. Mark Molitch, Professor of Medicine at Northwestern University Feinberg School of Medicine, has noted in his review of adult GHD management: "The diagnosis of adult GHD requires provocative testing with validated assays, and treatment decisions should be guided by the severity of deficiency and the patient's symptom burden" [12].

Sermorelin vs. Somatropin: A Direct Comparison

The comparison between sermorelin and somatropin is not a contest between equals. Somatropin is the evidence-based standard of care with multiple FDA-approved indications for adult GHD. Sermorelin is an off-label alternative with limited supporting data.

Efficacy: Somatropin reliably raises IGF-1 levels in a dose-dependent manner regardless of pituitary function. In the Cochrane review (11 RCTs, N=534), somatropin produced mean reductions in fat mass of approximately 3 kg and increases in lean mass of approximately 2.7 kg over 6 to 12 months [8]. Sermorelin's efficacy depends entirely on somatotroph reserve and has not been quantified in comparable RCTs.

Safety profile: Somatropin's long-term safety data span more than 30 years of post-marketing surveillance. The HypoCCS registry (Pfizer) followed over 6,000 adult GHD patients on somatropin and found no increased risk of cancer recurrence or new malignancy [13]. Sermorelin's long-term safety in adult GHD is unknown.

Cost: Somatropin ranges from $500 to $2,000+ per month depending on the brand and dose, though many manufacturers offer patient assistance programs. Compounded sermorelin typically costs $150 to $400 per month but is rarely covered by insurance.

Physiologic advantage (theoretical): Sermorelin preserves pulsatile GH release and activates the GH-IGF-1 negative feedback axis. In theory, this reduces the risk of supraphysiologic GH exposure that can occur with fixed-dose somatropin injections. No head-to-head trial has confirmed this translates into better clinical outcomes.

Convenience: Both require daily subcutaneous injection, though some newer somatropin formulations (Sogroya, lonapegsomatropin/Skytrofa) are weekly injections. No long-acting sermorelin formulation exists.

Regulatory and Legal Considerations

Prescribing compounded sermorelin is legal under current U.S. law, but the regulatory framework has important nuances. The Drug Quality and Security Act of 2013 established two categories of compounding: Section 503A (traditional pharmacy compounding under a valid patient-specific prescription) and Section 503B (outsourcing facilities that may compound without patient-specific prescriptions but must register with the FDA and comply with current good manufacturing practices) [4].

The FDA's Center for Drug Evaluation and Research (CDER) maintains a list of "bulk drug substances" permitted for compounding. Sermorelin acetate currently appears on the FDA's list of substances that may be used in compounding, but this status could change [4].

State-level regulations add another layer. Some state boards of pharmacy impose additional restrictions on peptide compounding. Clinicians should confirm that their compounding pharmacy operates in compliance with both federal and state requirements.

From a malpractice perspective, prescribing off-label carries higher medicolegal exposure than on-label use. Documentation should include the clinical rationale for choosing sermorelin over somatropin, evidence of informed consent covering the off-label status and limited evidence base, and objective monitoring data demonstrating treatment response.

Practical Considerations for Patients

Patients receiving compounded sermorelin should be aware of several practical points that affect day-to-day use.

Reconstitution: Sermorelin is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Most compounding pharmacies supply it pre-measured with instructions, but patients must handle the vial carefully. Once reconstituted, the solution should be refrigerated and used within 28 to 30 days.

Timing matters. Administering sermorelin at bedtime (30 to 60 minutes before sleep, on an empty stomach) aligns with the body's natural nocturnal GH pulse. Eating within 60 to 90 minutes of injection may blunt the GH response because postprandial hyperglycemia and hyperinsulinemia suppress GH release [3].

Expectations: Patients should expect gradual, modest improvements over weeks to months. The rapid, dramatic body composition changes sometimes promoted on wellness websites are not supported by the existing evidence. A realistic timeline for measurable IGF-1 changes is 4 to 8 weeks; for noticeable body composition shifts, 3 to 6 months.

When to stop: If IGF-1 has not increased by at least 20% from baseline after 8 to 12 weeks at 300 mcg nightly, the treatment is likely ineffective for that patient. Continuing indefinitely without biochemical evidence of response is neither cost-effective nor medically justified.

Baseline IGF-1 for a 50-year-old male is approximately 81 to 225 ng/mL (Mayo Clinic reference range), and the goal of therapy is to bring levels to the mid-to-upper portion of the age-appropriate range [2].